Investigators at Virginia Commonwealth University Massey Cancer Center are developing dynamical models that may allow clinicians to move beyond simple human leukocyte antigen matching to personalize immunosuppressive regimens and thus improve donor selection.
The Department of
at Virginia Commonwealth
Massey Cancer Center has
long been at the forefront
worldwide in the development
of various radiation
therapy technologies that
are now considered standard
and have become widely available.
Victor Y. Yazbeck, MD, discusses the potential for venetoclax and idelalisib, both as single agents and in combination with other agents, and what questions remain regarding both therapies in CLL.
The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.
Victor Y. Yazbeck, MD, assistant professor, Hematology-Oncology, Internal Medicine, Virginia Commonwealth University (VCU) School of Medicine, VCU Massey Cancer Center, discusses a phase III study examining idelalisib plus bendamustine rituximab in patients with relapsed/refractory chronic lymphocytic leukemia.
OncLive® announced an addition to its vibrant Strategic Alliance Partnership program today as VCU Massey Cancer Center signed onto the program's mission to raise awareness of cancer treatment and research.